leadf
logo-loader
viewPolarean Imaging PLC

Polarean Imaging on track to complete enrolment for its phase III clinical trials

Polarean Imaging PLC's (LON:POLX) chief executive Richard Hullihen talks Proactive London's Andrew Scott through the firm's 2018 results.

Polarean reported slightly higher revenues and lower costs than expected for the past calendar year.

It's currently taking its drug-and-device technology through late-stage clinical trials and he says they're on track to apply for regulatory permission in the US next year and deliver first commercial sales by end of the year.

Quick facts: Polarean Imaging PLC

Price: 40.5 GBX

AIM:POLX
Market: AIM
Market Cap: £65.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...

on 19/6/20

2 min read